Peptides, short chains of amino acids found naturally in the body and in animal venoms, are reshaping how researchers approach chronic pain. The therapeutic peptide market was valued at roughly $46 billion in 2024 and is expected to grow to nearly $69 billion by 2028, with pain management as one of its most active frontiers.1Oxford Academic (Pain Medicine). The Role of Peptides in Pain Management Unlike conventional painkillers that tend to act through a single receptor, many peptide-based approaches exploit the body’s own signaling systems or borrow molecular tools from venomous creatures to block pain at its source. The result is a rapidly expanding toolkit that may eventually offer strong pain relief with fewer of the side effects that have made opioid drugs so dangerous.
How Your Body Already Fights Pain With Peptides
Your nervous system has a built-in pain-dampening circuit, and endogenous opioid peptides are central to it. Enkephalins, endorphins, and dynorphins are all naturally occurring peptides that bind to opioid receptors on nerve cells. One of their key functions is modulating pain responses through a descending circuit that runs from the brain’s periaqueductal gray region down to the spinal cord, where it can dial down incoming pain signals before they ever reach conscious awareness.2PubMed Central. Endogenous opioid peptides in the descending pain modulatory circuit Techniques like acupuncture, transcutaneous electrical nerve stimulation, and spinal cord stimulation appear to work, at least partly, by triggering the release of these endogenous opioids.3Frontiers in Systems Neuroscience. The role of endogenous opioid neuropeptides in neurostimulation-driven analgesia
The problem is that the body breaks down its own pain-fighting peptides very quickly. Enkephalins, for instance, are chewed up within seconds by two enzymes in the brain and spinal cord. That rapid degradation limits their usefulness as a foundation for drugs, but it has inspired an entire line of research focused on slowing the breakdown rather than flooding the system with synthetic opioids from outside.
Dual Enkephalinase Inhibitors
Rather than introducing a foreign opioid, dual enkephalinase inhibitors, or DENKIs, work by protecting the enkephalins your body already produces. They block both of the enzymes responsible for chewing up enkephalins, which extends the peptides’ lifespan and amplifies their natural painkilling effects.4PubMed. Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management The appeal is that enkephalin levels rise only where and when pain signals trigger their release, so the system is self-regulating in a way that exogenous opioids are not.5PubMed. Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route
Animal studies and early clinical work suggest that DENKIs produce fewer side effects than conventional opioids, and some researchers have proposed they could serve as both a pain treatment and a potential therapy for opioid withdrawal, because they activate the same receptors in a more controlled, physiological manner.6PubMed. The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders The concept is elegant: instead of importing a powerful synthetic molecule that overwhelms the receptor system, you give the body’s own molecules a longer window to do their job.
Ziconotide and the Cone Snail Legacy
The first peptide approved by the FDA specifically for pain came not from a laboratory but from a marine cone snail. Ziconotide, approved in 2004, is a synthetic copy of a toxin produced by Conus magus. It works by blocking N-type calcium channels on nerve endings in the spinal cord, which prevents the release of pain-signaling chemicals.7PubMed Central. Ziconotide: a review of its pharmacology and use in the treatment of pain By interrupting nerve transmission at that level, it can provide powerful pain relief for people with severe chronic pain who have not responded to other treatments.8PubMed. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain
Ziconotide’s mechanism has nothing to do with opioid receptors, which means it carries no risk of respiratory depression or the addictive potential associated with morphine-type drugs. But it is far from a simple pill. The peptide must be delivered directly into the spinal fluid through an implanted pump, because it cannot cross the blood-brain barrier or survive digestion. And its therapeutic window is narrow. Early clinical use was plagued by side effects because doctors titrated the dose too quickly. At higher doses, patients experienced dizziness, nausea, confusion, visual disturbances, and abnormal gait.9PubMed Central. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain Slower titration schedules have improved tolerability, but ziconotide remains a last-resort option reserved for the most refractory cases.
Despite those limitations, ziconotide demonstrated something important: a peptide derived from an animal venom could become a real drug, and its success has fueled a wave of research into other venom-sourced peptides.
Spider Venom and Nav1.7 Blockers
If you could shut down a single sodium channel and eliminate pain without numbing everything else, you’d have an ideal painkiller. That is the promise behind Nav1.7, a voltage-gated sodium channel found primarily on pain-sensing neurons. People born with loss-of-function mutations in the gene encoding Nav1.7 feel virtually no pain, yet their other senses and motor function remain intact. That genetic observation has made Nav1.7 one of the most pursued drug targets in pain research.
Spider venoms are a rich source of peptides that interact with sodium channels, and researchers have been engineering these toxins to be more selective for Nav1.7 while leaving other sodium channel subtypes alone.10PubMed Central. Selective Targeting of Nav1.7 with Engineered Spider Venom-Based Peptides One well-characterized example, a peptide called Pn3a isolated from a tarantula species, inhibits Nav1.7 with 40- to over 900-fold selectivity compared to other sodium channel subtypes.11Scientific Reports. Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a That degree of selectivity matters because blocking closely related channels like Nav1.5, which is critical for heart rhythm, would be dangerous.
The challenge is translating selectivity in a lab dish into a working drug in a living person. Off-target effects remain a significant hurdle, and researchers are actively engineering modifications to improve both specificity and stability of these venom-derived peptides.12PubMed Central. Optimizing Nav1.7-Targeted Analgesics: Revealing Off-Target Effects of Spider Venom-Derived Peptide Toxins and Engineering Strategies for Improvement No spider-venom-derived Nav1.7 blocker has reached the market yet, but the pipeline continues to attract serious investment. Venom peptides that target other pain-relevant receptors, including the heat- and capsaicin-sensing TRPV1 channel, are also under investigation.13PubMed Central. Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development
CGRP and the Migraine Breakthrough
One of the most visible success stories for peptide-related pain therapy involves calcitonin gene-related peptide, or CGRP. This signaling molecule is released by sensory nerve fibers and contributes to neurogenic inflammation, the process where nerve activity itself promotes swelling and sensitivity in surrounding tissue. CGRP is upregulated in inflammatory and neuropathic pain states, and it plays a role in sensitizing both the initial pain-sensing neurons and the second-order neurons deeper in the spinal cord that relay pain signals to the brain.14PubMed Central. The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
In migraine specifically, CGRP release from nerve endings around blood vessels in the brain triggers vasodilation and sensitizes surrounding nociceptors, fueling the cascade of pain and sensory sensitivity that defines a migraine attack.15PubMed Central. Calcitonin gene-related peptide and pain: a systematic review The monoclonal antibodies and small-molecule antagonists that block CGRP or its receptor, drugs like erenumab, fremanezumab, and rimegepant, have transformed migraine prevention and treatment for millions of people. While these antibodies are proteins rather than small peptides, the entire therapeutic class exists because researchers mapped the role of a specific peptide in the pain pathway and then designed molecules to block it. CGRP’s involvement in non-migraine pain, including joint inflammation and neuropathic conditions, is an area of ongoing study.
Substance P and Pain Sensitization
Substance P is another peptide deeply embedded in pain signaling. It belongs to the tachykinin family, and together with its receptor, the NK1 receptor, it plays a well-established role in transmitting pain signals from the body’s periphery into the spinal cord.16PubMed. Involvement of substance P/NK1 receptor system in central sensitization in chronic pain Where CGRP amplifies and sensitizes, substance P is more directly involved in carrying the pain message itself.
Blocking the NK1 receptor looked extremely promising in the 1990s, and pharmaceutical companies invested heavily in NK1 antagonists as next-generation painkillers. The drugs worked well in animal models but repeatedly failed in human clinical trials for pain. One NK1 antagonist, aprepitant, did find a second life as an anti-nausea drug for chemotherapy patients, but the hoped-for pain indication never materialized. The disconnect between animal results and human outcomes remains one of the cautionary tales of peptide-based drug development. It is a reminder that targeting a single peptide pathway, even one unambiguously involved in pain transmission, does not guarantee a successful drug.
Multifunctional Peptides and Biased Agonists
Chronic pain, especially neuropathic pain from nerve damage, involves multiple overlapping signaling pathways. A drug that hits only one target may not provide adequate relief, or it may drive compensatory mechanisms that create new problems. This has motivated the design of multifunctional peptides: single molecules engineered to engage two or more targets simultaneously.
One approach creates peptides that activate both mu and delta opioid receptors while also blocking cholecystokinin (CCK) receptors, which normally counteract opioid pain relief. Compounds like RSA 504 and RSA 601 demonstrated exactly this combination in animal models of neuropathic pain, reducing sensitivity to both mechanical and heat stimuli without the typical side effects of conventional opioids.17PubMed Central. Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain Another line of research built on biphalin, a bivalent peptide that activates both mu and delta receptors with a cleaner side-effect profile than morphine, and then modified it into a more metabolically stable form called MACE2 that showed efficacy in several chronic pain models.18PubMed Central. Elucidation on the In Vivo Activity of the Bivalent Opioid Peptide MACE2 against Several Types of Chronic Pain
A related strategy is “biased agonism,” where a peptide activates the same receptor as morphine but preferentially triggers one downstream signaling cascade over another. The mu-opioid receptor can signal through G proteins, which produce pain relief, or through beta-arrestin, which is linked to respiratory depression and constipation. Biased agonist peptides like KGFF03 and KGFF09, which also antagonize neuropeptide FF receptors, showed reduced respiratory depression in mice compared to an unbiased opioid of similar potency.19Pain. A bifunctional-biased mu-opioid agonist–neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects These are still preclinical results, and biased agonism has stumbled before in late-stage trials with small-molecule drugs. But the peptide format gives chemists more structural flexibility to fine-tune signaling bias than traditional small molecules typically allow.
Neurotensin and Opioid-Free Pain Relief
Not every peptide approach to pain involves opioid receptors at all. Neurotensin is a 13-amino-acid peptide that acts through two receptor subtypes, NTS1 and NTS2, and researchers have shown that activating neurotensin pathways can reduce both inflammatory and neuropathic pain. In one study, neurons in the lateral hypothalamus that produce neurotensin were stimulated using a technique called chemogenetics, and the resulting pain relief was blocked when a neurotensin receptor antagonist was administered, confirming that the effect depended specifically on neurotensin signaling rather than some off-target mechanism.20Neurobiology of Pain. Neurotensin-expressing lateral hypothalamic neurons alleviate neuropathic and inflammatory pain via neurotensin receptor signaling
On the drug development side, researchers have created macrocyclic (ring-shaped) neurotensin analogs that are highly selective for NTS2, achieving roughly 30,000-fold selectivity over NTS1. These compounds produced potent opioid-independent pain relief in animal models and could potentially be used either on their own or alongside low-dose opioids to reduce opioid-related side effects.21PubMed. Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid-Free Analgesics The idea of “opioid-sparing” therapy, where a non-opioid drug allows a much lower opioid dose to achieve the same relief, is increasingly popular among pain researchers as a pragmatic middle ground between all-opioid and opioid-free strategies.
GLP-1 Receptor Agonists and an Unexpected Pain Connection
GLP-1 receptor agonists like semaglutide and liraglutide are best known for treating diabetes and, more recently, obesity. But emerging evidence suggests they may also dampen neuropathic pain. The proposed mechanism is not metabolic: GLP-1 receptors are expressed on glial cells and neurons in the spinal cord, and activating them appears to reduce neuroinflammation and central sensitization, the process by which the nervous system amplifies pain signals over time.22PubMed. GLP-1 Receptor Agonists in Neuropathic Pain and Neurodegenerative Diseases: Mechanisms, Therapeutic Potentials, and Future Perspectives This is still early-stage research, and it is worth being skeptical of any single mechanism explanation for drugs as widely studied as GLP-1 agonists. But if the pain-related findings hold up in larger clinical studies, a drug class already prescribed to millions could find an entirely new application.
The Delivery Problem
The biggest practical barrier for peptide painkillers is getting them where they need to go. Peptides are fragile. They are broken down in the gut, cleared rapidly from the bloodstream, and often cannot cross the blood-brain barrier, the tightly sealed layer of cells that separates blood vessels from brain tissue. Ziconotide’s requirement for an implanted intrathecal pump illustrates how severe this limitation can be.
Researchers are attacking the delivery problem from multiple angles. One approach is backbone cyclization, where the peptide’s chain is bent into a ring shape by connecting its two ends with a chemical bridge. This makes the molecule more resistant to the enzymes that would normally chop it apart. In one study, cyclization of a conotoxin called RgIA, which targets a nicotinic acetylcholine receptor subtype relevant to pain, improved its stability in human serum without disrupting the peptide’s three-dimensional shape.23PubMed. Effects of cyclization on stability, structure, and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABA(B) receptor Similar cyclization strategies have been applied to opioid peptides, producing analogs that can be taken orally and produce long-lasting, peripherally restricted pain relief with reduced side effects.24PubMed. Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects
For peptides that need to reach the brain, cell-penetrating peptides (CPPs) offer a shuttle service. These short amino acid sequences can cross cell membranes, and when attached to a therapeutic peptide, they can carry it across the blood-brain barrier. In one experiment, the natural opioid peptide endomorphin-1 was linked to a CPP called SynB3 using different chemical tethers, which improved its ability to cross into the brain.25PubMed. The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages A different strategy used angiopep-2, a peptide that hitches a ride on a transport receptor naturally present on blood-brain barrier cells, to ferry morphine and its metabolite M6G into the brain. The conjugate produced stronger and longer-lasting pain relief than equivalent doses of unconjugated morphine or M6G.26The Journal of Pharmacology and Experimental Therapeutics. Use of a Noninvasive Brain-Penetrating Peptide-Drug Conjugate Strategy to Improve the Delivery of Opioid Pain Relief Medications to the Brain If these shuttle strategies prove safe and scalable, they could eventually make intrathecal pumps unnecessary for some peptide drugs.
Immune Cells as Peripheral Pain Relievers
Pain does not only get managed in the brain and spinal cord. At sites of inflammation, immune cells that migrate to injured tissue carry their own supply of opioid peptides. When these cells arrive, they release enkephalins, endorphins, and dynorphins that bind to opioid receptors on nearby sensory nerve endings, producing measurable pain relief right at the source of the problem.27PubMed. Mechanisms of peripheral immune-cell-mediated analgesia in inflammation: clinical and therapeutic implications This peripheral opioid mechanism has been demonstrated in both animal models and human surgical settings.28PubMed. Immune cell-mediated opioid analgesia
The therapeutic implication is straightforward: if you can design peptides that activate peripheral opioid receptors without crossing into the central nervous system, you could potentially treat inflammatory pain without causing sedation, respiratory depression, or the euphoria that drives addiction. Some of the cyclic peptide designs mentioned earlier deliberately exploit this principle, producing compounds that stay in the periphery and act only where inflammation has upregulated opioid receptor expression. The concept is still largely preclinical, but it represents one of the cleaner paths toward separating pain relief from opioid side effects.
The Safety Question
A persistent hope in the peptide field is that peptide-based analgesics will be inherently safer than traditional opioids. The reasoning has several threads: peptides can be designed to stay outside the brain, they can exploit the body’s own regulatory mechanisms (as with DENKIs), and they can be engineered for biased signaling that avoids the pathways linked to dependence and respiratory depression. Overall, opioid peptides have been recognized as promising candidates for developing safer analgesics, and strategies like multifunctional design, biased agonism, and peripheral restriction have all shown reduced side effects in animal models.29PubMed Central. Peptide-derived ligands for the discovery of safer opioid analgesics
But “safer in mice” is a familiar refrain in drug development, and the history of pain therapeutics is littered with molecules that looked cleaner in animal studies than they turned out to be in people. Ziconotide’s rocky early clinical experience is one example: the drug is genuinely non-addictive and does not suppress breathing, but its neurological side effects required careful management that took years to optimize.9PubMed Central. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain Another cone snail-derived peptide, Xen2174, which works by blocking norepinephrine reuptake in the spinal cord, was tested via intrathecal injection in a clinical trial. The most common adverse event was post-lumbar-puncture syndrome, and the highest dose group exceeded a predefined safety margin based on cerebrospinal fluid drug levels, underscoring how tricky dosing can be for intrathecally delivered peptides.30PubMed Central. Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties
Living With an Intrathecal Pump
For the small number of patients currently receiving peptide-based pain therapy, the experience is defined by the delivery device as much as by the drug. Intrathecal pumps are surgically implanted under the skin of the abdomen and connected to a catheter threaded into the spinal fluid. They deliver tiny, precisely metered doses of medication directly to the spinal cord. The growing number of patients with these implanted devices means that more people are showing up for unrelated surgeries and procedures while carrying an active drug pump, and there is surprisingly little consolidated guidance on how to manage them during those encounters.31PubMed Central / Wiley Online Library. Perioperative and Periprocedural Care of Patients With Intrathecal Pump Therapy Patients need to coordinate with multiple specialists, watch for catheter-related complications, and attend regular refill appointments. It is effective therapy for some people with truly severe, otherwise-untreatable pain, but it is a commitment that shapes daily life in ways a pill never would.
This reality is exactly what motivates the push toward oral and injectable peptide formulations. If cyclization, CPP shuttles, and other engineering strategies can eventually produce peptide painkillers that survive the gut and reach their targets without a pump, the patient experience would change dramatically. For now, though, the gap between laboratory promise and bedside convenience remains the field’s defining challenge.